Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback